JP2005519073A - 睡眠標的モジュレーターを使用する睡眠障害の治療 - Google Patents

睡眠標的モジュレーターを使用する睡眠障害の治療 Download PDF

Info

Publication number
JP2005519073A
JP2005519073A JP2003567333A JP2003567333A JP2005519073A JP 2005519073 A JP2005519073 A JP 2005519073A JP 2003567333 A JP2003567333 A JP 2003567333A JP 2003567333 A JP2003567333 A JP 2003567333A JP 2005519073 A JP2005519073 A JP 2005519073A
Authority
JP
Japan
Prior art keywords
compound
group
therapeutic compound
therapeutic
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003567333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519073A5 (https=
Inventor
デービッド ジー． ハンガウアー，
ハリー ジェファーソン レイトン，
デール エム． エドガー，
Original Assignee
ヒプニオン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヒプニオン， インコーポレイテッド filed Critical ヒプニオン， インコーポレイテッド
Publication of JP2005519073A publication Critical patent/JP2005519073A/ja
Publication of JP2005519073A5 publication Critical patent/JP2005519073A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003567333A 2002-01-18 2003-01-21 睡眠標的モジュレーターを使用する睡眠障害の治療 Withdrawn JP2005519073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34991202P 2002-01-18 2002-01-18
US35732002P 2002-02-15 2002-02-15
PCT/US2003/001845 WO2003068148A2 (en) 2002-01-18 2003-01-21 Treatment of sleep disorders using sleep target modulators

Publications (2)

Publication Number Publication Date
JP2005519073A true JP2005519073A (ja) 2005-06-30
JP2005519073A5 JP2005519073A5 (https=) 2005-12-22

Family

ID=27737408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003567333A Withdrawn JP2005519073A (ja) 2002-01-18 2003-01-21 睡眠標的モジュレーターを使用する睡眠障害の治療

Country Status (6)

Country Link
US (2) US20030232839A1 (https=)
EP (1) EP1471913A2 (https=)
JP (1) JP2005519073A (https=)
AU (1) AU2003210598A1 (https=)
CA (1) CA2473586A1 (https=)
WO (1) WO2003068148A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047759A1 (es) * 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
US20080167248A1 (en) * 2004-04-26 2008-07-10 Immuneregen Biosciences, Inc. Anti-Aging Effects Of Substance P
JP4613031B2 (ja) * 2004-05-06 2011-01-12 エスエス製薬株式会社 催眠剤組成物
PT1931346E (pt) * 2005-09-09 2012-08-14 Angelini Labopharm Llc Composição de trazodona para administração uma vez por dia
WO2007048219A2 (en) * 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
WO2007098200A2 (en) 2006-02-16 2007-08-30 Imthera Medical, Inc. An rfid-based apparatus, system, and method for therapeutic treatment of obstructive sleep apnea
WO2008070795A2 (en) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
EP2197536A1 (en) 2007-10-09 2010-06-23 Imthera Medical, Inc. System and method for neural stimulation
BRPI0920548B8 (pt) 2008-10-09 2021-06-22 Imthera Medical Inc aparelho para controlar posição da língua de um paciente
ATE522169T2 (de) † 2009-10-23 2011-09-15 Gruppo Cimbali Spa Kaffeemaschine mit abgabedruckregulierung und damit zusammenhängendes verfahren
JP2013509943A (ja) 2009-11-10 2013-03-21 イムセラ・メディカル・インコーポレーテッド 舌下神経を刺激して患者の舌の位置を調節するシステム
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
WO2012109216A1 (en) 2011-02-11 2012-08-16 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
US9266881B2 (en) 2011-11-14 2016-02-23 Merck Sharp & Dohme Corp. Triazolopyridinone PDE10 inhibitors
CA2909591C (en) 2013-04-23 2017-03-28 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
KR102597910B1 (ko) 2015-03-26 2023-11-02 재클린 엠. 이베르센 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물
HUE058725T2 (hu) * 2018-04-06 2022-09-28 Basf Se Eljárás aminok elõállítására
WO2024102458A1 (en) * 2022-11-11 2024-05-16 Gilgamesh Pharmaceuticals, Inc. Methods of using trazodone to reverse the effects of 5-ht2a receptor agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116852A (en) * 1990-12-03 1992-05-26 Bristol-Myers Squibb Co. Treatment of sleep disorders

Also Published As

Publication number Publication date
WO2003068148A3 (en) 2004-04-01
AU2003210598A2 (en) 2003-09-04
EP1471913A2 (en) 2004-11-03
WO2003068148A2 (en) 2003-08-21
CA2473586A1 (en) 2003-08-21
US20060009465A1 (en) 2006-01-12
AU2003210598A1 (en) 2003-09-04
US20030232839A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
JP2005519073A (ja) 睡眠標的モジュレーターを使用する睡眠障害の治療
JP2005529840A (ja) Ｃｎｓ標的モジュレータを使用するｃｎｓ障害の治療
US20050080265A1 (en) Treatment of CNS disorders using CNS target modulators
JP2008531714A (ja) 不安障害の治療用及び／又は予防用の医薬組成物
CA2608024A1 (en) Use of flibanserin in the treatment of chronic pain
WO2007093624A2 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
JP2026035701A (ja) 神経学的および精神障害の治療方法
JP2550455B2 (ja) ４ーアルキルイミダゾール誘導体
CN1143321A (zh) 用5-ht2拮抗剂治疗观念与行为强迫症的方法
JP2009541484A (ja) ５ｈｔ６モジュレーターおよびコリンエステラーゼインヒビターを含む組み合わせ
JPH085787B2 (ja) 痴呆及び脳血管障害予防・治療剤並びに血小板凝集抑制剤
JPH01197469A (ja) ピペリジニル化合物類
JP2701933B2 (ja) ２―アルキル―３―ベンゾイルベンゾフラン類及びそれらを含有する医薬組成物
US5288750A (en) Substituted β-diketones
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
US7189757B2 (en) Treatment of sleep disorders using CNS target modulators
CN115304593A (zh) 苯并异噻唑化合物及其药物组合物和应用
JPH06511231A (ja) ２−（ピロリジニル−１−メチル）−ピペリジン誘導体およびκ受容体アゴニストとしてのその使用
JPH10513479A (ja) 芳香環にフェニル置換基を有するテトラリン、および癲癇、卒中、および脳または脊髄外傷の処置におけるその使用
JP5745501B2 (ja) ベンズアニリド誘導体
JPWO2005113501A1 (ja) 神経因性疼痛制御剤組成物
JPS60255781A (ja) ラクトン誘導体、その製法及びそれを含む医薬組成物
JP2008106028A (ja) 慢性疼痛の治療におけるフリバンセリンの使用
JPH03291261A (ja) ω−アミノ−フェニルアルカノニトリル誘導体
IL160486A (en) Citalopram for the treatment of elevated blood pressure

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060404